CSF2 and neuroblastoma: Additionally, Naxitamab, another humanized (IgG1) anti-GD2 antibody (hu3F8) has demonstrated superior ADCC and clinical efficacy in combination with granulocyte macrophage colony-stimulating factor (GM-CSF), gaining approval by Food and Drug Administration in 2020 for treatment of high-risk NB [32].